Recommended for its ‘strong industry knowledge’, Carpmaels & Ransford LLP is well-known for its ability to advise healthcare and life sciences clients in EPO oppositions, strategic prosecutions, and patent and SPC litigation. The practice is jointly led by David Wilson, who is entrusted by science and technology players to assist with multi-jurisdictional litigation, Hugh Goodfellow, and Jake Marshall, who helms the transactional group with his expertise in IP and technology. Other key names to note in the practice include Camilla Balleny, who is well-versed in patent litigation as well as advisory work, and Ian Kirby, whose arsenal of skills encompass monoclonal antibodies and voice recognition technologies, among others. Jennifer Antcliff enjoys considerable litigation experience, having represented clients in the High Court, Court of Appeal, and Supreme Court. Craig Lumb is also recommended.
Legal 500 redaktioneller Kommentar
- Profil
Auszeichnungen
Mandantenzufriedenheit
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘The Carpmaels team has strong industry knowledge and does a great job integrating litigators with the patent attorney team.’
- 'David Wilson is a strong leader.’
- 'Very well-supported IP team with the patent prosecution back up.'
- 'Ian Kirby is an excellent leader.'
Kernmandanten
- Sanofi-Aventis
- Johnson & Johnson group
- FibroGen, Inc.
- Novartis
- AMO Development, LLC
- Takeda
- Regeneron Pharmaceuticals, Inc.
- Bristol Myers Squibb
- Sidley Austin
Highlight-Mandate
- Representing Sanofi & Regeneron and Amgen in handling a long-running project involving EPO patent prosecution, EPO oppositions, national litigation support, and most recently UPC litigation relating Sanofi & Regeneron's Praluent® anti-PCSK9 antibody product and Amgen's competing Repatha® product.
- Representing Johnson & Johnson in defending and enforcing its patents that protect their biggest product, Stelara, which is a biological product used in the treatment of autoimmune diseases.
- Assisting Janssen with the revocation of certain antibody patents owned by Amgen at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI, Janssen’s first-in-class bispecific antibody therapy for treating multiple myeloma, an incurable blood cancer.
Anwält*innen
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Führende Associates
Führende Associates sind regelmäßig an zentralen Mandaten des Teams beteiligt und erhalten positives Feedback von Wettbewerbern oder Mandanten.
Craig Lumb
Praxisleitung
David Wilson; Hugh Goodfellow; Jake Marshall
Weitere Kernanwält*innen
Camilla Balleny; Ian Kirby; Jake Marshall; Jennifer Antcliff; Simon Llewellyn; Agathe Michelde Cazotte; Craig Lumb